Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Aspira Labs Wins Coverage from CareFirst BCBS for OVA1

NEW YORK (GenomeWeb) – Vermillion said today that CareFirst BlueCross BlueShield (BCBS) has agreed to cover its OVA1 ovarian cancer test.

CareFirst BCBS covers more than 3 million patients in Maryland, Washington DC, and Virginia.

"This is our fourth recent announcement of new managed care contracts as we continue to expand our reach in our key strategic market areas," Valerie Palmieri, Vermillion's president and CEO said in a statement. Most recently, the company signed an agreement in July with Michigan healthcare insurance company Priority Health Managed Benefits.

OVA1 is a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.